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Abstract
Purpose—Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-
lyase (lyase) and androgen receptor (AR) inhibitor with in vitro and in vivo anti-tumor activity. 
This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK) and 
activity of once-daily (QD) seviteronel in women with locally advanced or metastatic TNBC or 
ER+ breast cancer.
Methods—Seviteronel was administered in de-escalating 750 mg, 600 mg and 450 mg QD 6-
subject cohorts. The 750 mg QD start dose was a phase 2 dose determined for men with castration-
resistant prostate cancer [1]. Enrollment at lower doses was initiated in the presence of dose-
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limiting toxicities (DLTs). The primary objective of this study was to determine seviteronel safety, 
tolerability and MTD. The secondary objectives included description of its PK in women and its 
initial activity, including clinical benefit rate at 4 (CBR16) and 6 months (CBR24).
Results—Nineteen women were enrolled. A majority of adverse events (AEs) were Grade (Gr) 
1/2, independent of relationship; the most common were tremor (42%), nausea (42%), vomiting 
(37%) and fatigue (37%). Four Gr 3/4 AEs (anemia, delirium, mental status change and 
confusional state) deemed possibly related to seviteronel occurred in four subjects. DLTs were 
observed at 750 mg (Gr 3 confusional state with paranoia) and 600 mg (Gr 3 mental status change 
and Gr 3 delirium) QD, with none at 450 mg QD. The recommended phase 2 dose (RP2D) was 
450 mg QD, and at the RP2D, 4 of 7 subjects reached at least CBR16 (2 TNBC subjects and 2 ER
+ subjects achieved CBR16 and CBR24, respectively); no objective tumor responses were 
reported.
Conclusions—Once-daily seviteronel was generally well tolerated in women with and 450 mg 
QD was chosen as the RP2D.
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Introduction
The underlying molecular heterogeneity of breast cancer is well-recognized in the literature. 
Each breast cancer subtype is characterized by varied risk factors, clinicopathologic and 
molecular features, responses to therapy, patterns of recurrence, and clinical outcomes. 
Molecular profiling has led to the classification of breast cancer into reproducible subgroups 
[2–4]. Furthermore, these advances have enabled investigators to identify novel targets for 
the development of potential therapeutic interventions. The androgen receptor (AR) is one 
such target. AR is expressed in 70–90% of all invasive breast cancers [5–7]. Emerging data 
suggest that the AR-signaling pathway may play a critical role in breast cancer pathogenesis.
Several groups have described a population of triple negative breast cancer (TNBC) which 
demonstrates a gene expression signature resembling that of endocrine responsive tumors. 
This subtype is characterized by expression of AR and exhibits androgen-dependent, 
estrogen-independent growth in preclinical models [8–10]. The current standard of care in 
the treatment of TNBC is limited to traditional cytotoxic chemotherapy. The development of 
well-tolerated, effective, and targeted regimens that delay the need for cytotoxic 
chemotherapy and its side effects is an unmet need. Three early phase prospective clinical 
studies investigating antiandrogen therapy have demonstrated clinical benefit of AR-targeted 
agents in women with metastatic AR+ TNBC [11–13].
Similar to TNBC, the role of AR in the management of estrogen receptor-positive (ER+) 
breast cancer is an area of active research. AR is expressed in up to 90% of ER+ tumors and 
preclinical data suggests that AR expression is associated with resistance to both tamoxifen 
and aromatase inhibitors in ER+ cell lines [14–16]. While initially beneficial, resistance to 
endocrine therapy eventually develops in the majority of patients with ER+ breast cancer. As 
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a result, the question of how best to manage patients in this endocrine resistant setting has 
become a significant clinical concern. Tamoxifen-resistant breast tumors have been shown in 
preclinical models to have elevated AR expression along with reduced ERα mRNA levels, 
and treatment with antiandrogens in this setting resulted in reversal of tamoxifen resistance 
[14–16]. Aromatase inhibitors are widely used in women with postmenopausal hormone 
receptor-positive (HR+) breast cancer in both the adjuvant and metastatic setting. 
Investigators have reported that resistance to aromatase inhibition may involve AR 
activation, as sensitivity to anastrozole in preclinical models was restored using the 
antiandrogen, enzalutamide, and the CYP17 inhibitor, abiraterone acetate [17]. Furthermore, 
AR contributed to ERα transcriptional activity in MCF7 cells co-expressing AR and 
aromatase, which could then be inhibited with use of bicalutamide [17]. These data suggest 
a role for AR in resistance to estrogen targeted therapies that may be overcome by inhibition 
of AR. We hypothesize that an agent that combines AR inhibition with decreased sex steroid 
production (e.g., androgens and estrogens) will demonstrate clinical benefit in both HR− and 
HR+ breast cancer, including the subset of women with endocrine resistant tumors.
Seviteronel (INO-464) is an orally bioavailable, selective cytochrome P450c17a (CYP17) 
17,20 lyase (lyase) and AR inhibitor. It is approximately 10-fold selective for CYP17 lyase 
versus CYP17 17-α hydroxylase (hydroxylase) inhibition [18]. Seviteronel inhibits the AR 
through competitive antagonism of both wild-type and mutated forms (e.g., F876L and 
T877A) of the receptor [19]. Through this unique dual mechanism of action, seviteronel 
inhibits androgen production, thus reducing downstream estrogen aromatization from 
androgens, while also inhibiting AR binding and activation.
Seviteronel has been shown to inhibit the growth in multiple breast cancer models, both in 
vitro and in vivo [20]. Seviteronel inhibited estrogen-stimulated proliferation and cell growth 
in a soft agar assay of MCF7 (ER+/low AR expression), H16N2 (AR-/PR-/low ER 
expression) cellular proliferation, the growth of tamoxifen-resistant MCF7 cells (TAMR), 
and DHT-stimulated growth of MDA-MB-453 cells (ER−/AR+), all with higher potency/
efficacy than enzalutamide. Furthermore, seviteronel inhibited tumor growth and increased 
survival compared to enzalutamide in a tamoxifen-resistant MCF7 mouse xenograft model.
This report provides safety, tolerability and pharmacokinetic findings from a phase 1 study 
of seviteronel in women with advanced TNBC or ER+ breast cancer and also provides 
preliminary insight into the endocrine response and clinical benefit of dual inhibition of 
CYP17 lyase and the AR.
Subjects and Methods
Major Eligibility Criteria
Women with documented histological or cytological evidence of unresectable locally 
advanced or metastatic breast cancer that was either ER−, PR− and HER2−, or ER+ and 
HER2− were enrolled. There was no requirement for subjects to be AR+ for phase 1 study 
entry. Archival tumor samples were collected when available for future AR status 
determination to allow for potential inclusion in the planned phase 2 expansion. Female 
subjects with ER+ breast cancer must have been postmenopausal (or currently undergoing 
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ovarian suppression using LHRH agonists) and had disease progression following at least 
one line of prior endocrine therapy, which may have included progression within 6 months 
of adjuvant endocrine therapy. There was no restriction on the number of prior therapies for 
women with TNBC. Prior use of investigational agents that inhibited CYP17 or the AR was 
allowed. The presence of CNS metastases was not exclusionary, provided the subject was 
asymptomatic. Eligibility required an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 or 1, WBC ≥3,000/, ANC ≥1,500/μl, platelet count ≥100,000/
μl ,HGB ≥ 10 g/dl and not transfusion dependent, AST and ALT levels ≤3X the upper limit 
of normal (ULN), bilirubin levels of ≤2.0 mg/dl, serum creatinine of ≤2.0 mg/dl and K+ 
>3.5 mEq/l. Subjects who required pharmacological or replacement doses of systemic 
corticosteroids or were administered systemic corticosteroids within 7 days of study drug 
administration were ineligible.
Study Design and Treatment
The primary objective of this phase 1 study was to determine the safety, tolerability and 
maximum tolerated dose (MTD) of oral seviteronel administered once daily (QD) in women 
with triple negative unresectable locally advanced or metastatic breast cancer, or post-
menopausal women with ER+/HER2− unresectable locally advanced or metastatic breast 
cancer breast cancer. The secondary objectives of the phase 1 study were to describe the 
pharmacokinetics (PK) of QD seviteronel and estimate its efficacy using clinical benefit rate 
at 16 weeks (CBR16 for TNBC) and clinical benefit rate at 24 weeks (CBR24 for ER+ 
breast cancer). Clinical benefit was defined as either stable disease, partial response or 
complete response based upon RECIST 1.1. The study was approved by the institutional 
review board at each site. Informed consent was obtained from all individual participants 
included in the study.
Seviteronel was administered orally as 150 mg tablets in de-escalating dose cohorts of 750 
mg QD, 600 mg QD and 450 mg QD. The 750 mg QD start dose was a phase 2 dose 
determined for men with castration-resistant prostate cancer [1]. Study drug was 
administered in 28-day continuous dosing cycles. Study drug was discontinued if they were 
no longer clinically benefitting, an adverse event that precluded further participation in the 
study, or withdrawal of consent.
Six subjects were enrolled in sequential dose-level cohorts starting at 750 mg QD. Dose-
limiting toxicity (DLT) was defined as any Grade 3 or greater adverse event possibly/
probably/definitely related to seviteronel that occurred from the first dose of study drug 
through the end of the first 28-day continuous dosing cycle (Cycle 1). Two or more DLTs in 
a cohort resulted in opening the next lower dose-level cohort to six subjects. MTD was 
defined as the highest dose-level in which the incidence of DLTs was less than 33%. 
Toxicity was graded using the NCI Common Terminology Criteria for Adverse Events (NCI 
CTCAE), version 4.03.
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Baseline evaluations were conducted within 28-days of study drug initiation and included 
medical history, physical exam, vital signs, ECOG performance status, ECG, CBC and 
serum chemistries, urinalysis and imaging assessments.
Repeat evaluations were conducted bi-weekly for Cycle 1 and then monthly thereafter 
through the end of treatment visit. Efficacy assessments by imaging were repeated every 2 
months for the first year on study then every 3 months thereafter. The evaluation included all 
appropriate radiographic or scintigraphic procedures to document areas of metastatic 
disease, including bone scans, computed tomography scans and/or magnetic resonance 
imaging dependent upon what modality was utilized at baseline to assess metastatic disease.
Endocrine Analysis
Blood samples were collected for serum estradiol and testosterone concentration 
determination at baseline and the end of Cycle 1. Endocrine samples were analyzed using a 
central lab (inVentiv Health Clinical Lab, Inc., Princeton, NJ). The lower limits of 
quantitation for serum estradiol and testosterone assessed using gas chromatography–tandem 
mass spectrometry were 2.3 pmol/L and 86.7 pmol/L, respectively.
Pharmacokinetic Analysis
Blood samples for pharmacokinetic (PK) analysis were collected prior to first dose of 
seviteronel and 0.5, 1, 2, 4, 6, 8, and 24 hours after seviteronel dose. Additional samples 
were collected at Cycle 1 Day 14, Cycle 2 Day 1 and then every even-numbered cycle for 
spot PK analysis. The lower limit of quantification of seviteronel concentration in plasma 
when analyzed using liquid chromatography–tandem mass spectrometry was 20 ng/mL 
(0.05 uM) (Tandem Laboratories, Durham, NC). Dense PK parameters were analyzed by 
noncompartmental methods using WinNonlin (Certara, Princeton, NJ).
Results
Subject Characteristics
A total of 19 women with ER+ (n = 14) or TNBC (n = 5) were enrolled from August 2015 to 
March 2016 with data presented as of 26 October 2017. Baseline characteristics, including 
disease status and prior lines of therapy are presented in Table 1. Most subjects (83–100% 
depending upon dose-level cohort) had received two or more lines of prior therapy for 
advanced disease. Only 1 subject (5%) had locally advanced disease and none had bone only 
disease; a majority of women (84%) had visceral disease
Dose De-Escalation
Out of the 6 subjects enrolled at 750 mg QD, one DLT reported (Gr 3 confusional state with 
paranoia, considered possibly related to study drug). Six subjects were then enrolled at 600 
mg QD; two DLTs reported (Gr 3 mental status change and Gr 3 delirium, both considered 
possibly related to study drug). Seven subjects were enrolled at 450 mg QD; one subject was 
replaced at Day 22 of Cycle 1 due to dyspnea associated with disease progression. No DLTs 
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were observed at 450 mg QD. The recommended phase 2 dose (R2PD) for seviteronel in 
women was determined to be 450 mg QD.
Tolerability
An overview of treatment-emergent AEs is presented in Table 2 and Table 3. Treatment with 
seviteronel was generally well tolerated, with the majority of AEs Gr 1 or 2. The most 
common AEs were tremor (42%), nausea (42%), vomiting (37%) and fatigue (37%), 
independent of relationship. Four subjects reported AEs Gr 3 or greater. As per the 
investigator possibly related to seviteronel (anemia [450 mg QD], delerium [600mg QD], 
mental status change [600 mg QD] and confusional state [750 mg QD]). Four 4 deaths were 
reported and all were considered unrelated to study drug by the investigator (disease 
progression [n=2], hepatic failure [n=1] and ischemic stroke [n=1]). Fifteen serious adverse 
events (SAE) Gr 3 or greater were reported in 12 subjects with 3 events considered at least 
possibly related to seviteronel (delirium [600mg QD], mental status change [600 mg QD] 
and confusional state [750 mg QD]).
Overall median treatment duration was 43 days (13, 257) and with the longest median 
duration observed in the 450 mg QD cohort (136 days [22, 257]). All subjects are 
discontinued from study (Table 4). Treatment duration and reason for discontinuation are 
presented in Figure 1. Progressive disease was the most prevalent reason for treatment 
discontinuation across all dose cohorts. Twenty-one percent (4/19) of subjects underwent a 
dose reduction due to an AE, which typically resulted in an improvement in the AE.
Pharmacodynamic Effects
Serum estradiol and testosterone concentrations were determined at baseline and Cycle 2 
Day 1. Across dose-level cohorts, there were 6 subjects evaluable for analysis. Median 
decline in estradiol across dose-level cohorts was -52% (−29, −89), and median testosterone 
decline was −59% (−45, −76). Individual steroid reductions are presented in Supplemental 
Figure 1.
Pharmacokinetics
A noncompartmental PK summary is presented in Table 5. Plasma concentrations after a 
single dose of seviteronel from subjects in the 450 mg, 600 mg and 750 mg cohorts are 
presented in Supplemental Figure 2. A comparison of seviteronel exposure to body surface 
area (BSA) and body mass index (BMI) in women at 450 mg, 600 mg and 750 mg QD is 
presented in Supplemental Figure 3.
Efficacy
Five of 19 subjects (26.3%) and 2 of 19 (11%) across dose groups reached at least CBR16 
and CBR24, respectively (Figure 1). In the 450 mg QD cohort, which was the RP2D, 4 of 7 
subjects reached at least CBR16 (2 TNBC subjects and 2 ER+ subjects achieved CBR16 and 
CBR24, respectively). No objective tumor responses were reported.
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The results of this phase 1 clinical study demonstrate that seviteronel is generally well-
tolerated in subjects with advanced breast cancer. Based upon the safety and tolerability in 
the current phase 1 study, the recommended phase 2 dose of seviteronel in women was 
determined to be 450 mg QD. Pharmacodynamic effect was observed with decline in 
estrogen and testosterone consistent with CYP17 lyase inhibition, and preliminary evidence 
of clinical benefit was noted in a heavily pretreated population warranting further evaluation 
in breast cancer.
The most common adverse events with seviteronel were tremors, nausea, vomiting, fatigue, 
blurred vision, and dizziness. Some of these adverse effects, such as nausea, fatigue and 
decreased cognition have been reported with other anti-androgens [11,21,12]. However, 
unlike bicalutamide, seviteronel was not associated with hepatic transaminase elevation [11]. 
One of the most common toxicities of abiraterone is hypokalemia, secondary to 
hypermineralocorticoidism. This was not seen with seviteronel, highlighting the selectivity 
of CYP17 lyase inhibition [21].
Human genetic mutations that lead to isolated CYP17 lyase deficiency or combined CYP17 
hydroxylase/lyase deficiency result in potent sex steroids decreases, whereas only the latter 
results in significant progesterone increases and significant cortisol decreases [22,23]. While 
seviteronel is a potent and selective CYP17 lyase inhibitor, its lyase activity is not 
completely isolated from hydroxylase; it still harbors some activity against CYP17 
hydroxylase. Significant CYP17 hydroxylase inhibition results in cortisol suppression and 
an increase in ACTH, which can drive upstream steroid accumulation, including 
corticosterone and the associated mineralocorticoid excess syndrome (MES) [24]. 
Significant CYP17 hydroxylase inhibition does not appear to be occurring in men or women 
treated with seviteronel as the common signs and symptoms of MES, which include 
hypertension, hypokalemia, and fluid overload, were not observed in the current study or in 
men with CRPC treated with seviteronel [25] (Gupta et al, submitted). However, the most 
common AEs observed with seviteronel, including those that appear to have a CNS origin, 
are also found in patients experiencing adrenal glucocorticoid insufficiency [26–28], 
suggesting minor CYP17 hydroxylase inhibition. Accordingly, to ameliorate associated AEs, 
the addition of the glucocorticoid mimetic dexamethasone to seviteronel is currently being 
investigated in ongoing breast and prostate cancer studies.
Across doses examined in women, there was a dose-proportional relationship for peak and 
trough plasma drug concentrations, and overall exposure (AUC), after a single dose of 
seviteronel. Half-life ranged from 6.4 to 8.4 hours, supporting once daily dosing. These 
results are similar to phase 1 seviteronel PK results in men with CRPC with regards to 
plasma half-life and dose-proportional drug exposure relationship (Gupta et al, submitted).
In the current study, the median decline in estradiol was 52% with seviteronel after one 
month of treatment across dose groups. By comparison, in postmenopausal women with ER
+ BC treated with letrozole, a non-steroidal aromatase inhibitor, there is an approximately 
36% decline in estradiol by 3 months of treatment [29]. In a similar group of women treated 
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with abiraterone + prednisone, estradiol concentrations declined to an extent similar to 
women receiving exemestane alone [30]. This is in contrast to enzalutamide where there is 
13% increase in estradiol when given in combination with exemestane and a 40% increase 
when given in combination with anastrozole [31].
The median decline in testosterone across dose groups was 59% in the current study. Potent 
(94%) declines in testosterone were observed after one month of treatment with abiraterone/
prednisone, but this was accompanied by significant increases in progesterone 
concentrations (2,666%), which was considered a major reason for a lack of overall clinical 
benefit of abiraterone/prednisone in this population [21,30].
Abiraterone is a steroidal CYP17 inhibitor with potent hydroxylase activity, and given its 
lack of lyase selectivity it is not surprising that progesterone concentrations were elevated, as 
is the case with men treated with abiraterone/prednisone [24]. Significant progesterone 
elevations do not occur in men (Gupta et al, submitted) or women treated with seviteronel 
[data on file], which is in line with the CYP17 lyase activity of seviteronel. The same is true 
for castrate male rhesus monkeys: progesterone concentrations remained unchanged with 
seviteronel treatment, but were significantly increased with abiraterone [32].
The maximum plasma concentration of seviteronel in women at 450 mg QD (recommended 
phase 2 dose) was similar to that achieved with the recommended phase 2 dose in men of 
600 mg QD (Gupta et al, submitted). When exposure results from the three dose levels were 
combined, there was a moderate relationship between exposure and body surface area and 
body mass index. Given the moderate relationship and for patient convenience, a single fixed 
dose is being chosen for further phase 2 development in women.
In this study, which enrolled a heavily pre-treated population with most (84%) having 
visceral disease, the 16- and 24-week CBR was 26.3% and 11% respectively. The primary 
objective of the current study was to determine the safety and tolerability of seviteronel and 
not clinical activity, therefore AR status determination or positivity was not required. That 
being said, these results are comparable with other early-phase breast cancer studies 
investigating anti-androgens as monotherapy where subjects were AR+. In a phase 2 study 
(TBCRC011), investigating bicalutamide in subjects with AR+ (ER−/PR−) metastatic breast 
cancer (N = 26), the 24-week CBR was 19%, median progression-free survival (PFS) was 12 
weeks, and no objective responses were seen [11]. Similarly, in the MDV3100-11 study, 
investigating enzalutamide in subjects with AR+ TNBC (N =118; intent to treat population 
with AR > 0%), the 16-week and 24-week CBR was 25% and 20%, respectively and median 
PFS was 12.6 weeks (12). Regarding abiraterone, a 24-month CBR of 22% was reported in 
subjects with metastatic ER+/AR+ breast cancer (N = 32; evaluable population with AR ≥ 
1%) [33], and 24-month CBR of 20% among subjects with metastatic AR+ TNBC (N = 30; 
evaluable population with AR ≥ 10%) [12].
Besides monotherapy, clinical studies have also investigated the combination of anti-
androgens with endocrine therapy in ER+ advanced breast cancer. In a phase 1/1b study, 
investigating enzalutamide in combination with endocrine therapy among subjects with 
advanced ER+ breast cancer (N = 70), the CBR 16 was noted to be 9%, but one subject 
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experienced stable disease for more than 3 years. Similarly, in a randomized phase 2 study 
investigating abiraterone in subjects with metastatic ER+ breast cancer (N = 297), there was 
no significant difference in median PFS in subjects receiving abiraterone plus exemestane 
(4.5 months) versus abiraterone alone (3.7 months) or exemestane alone (3.7 months) [21]. 
However, subjects who had dual AR+/ER+ disease, as detected by fresh biopsies or 
circulating tumor cells, had a significantly higher PFS with abiraterone plus exemestane, as 
compared to exemestane alone [30] highlighting the need of predictive biomarker for subject 
selection in studies investigating AR directed therapy in breast cancer.
Furthermore, the landscape of ER+ breast cancer has changed with the approval of mTOR 
and CDK 4/6 inhibitors [34–37]. The combination of seviteronel and everolimus 
demonstrated synergy in breast cancer cellular proliferation models including AR+ TNBC 
[38]. Whether the combination of seviteronel with everolimus or investigational targeted 
therapies will result in better outcomes is unclear and warrants further studies.
In conclusion, oral seviteronel is generally well tolerated at 450 mg daily dosing and is the 
recommended phase 2 dose for women with breast cancer. Seviteronel’s dual mechanism of 
action with reduced sex-steroid production and AR antagonism may provide a unique 
treatment option, even in the endocrine-failure population. Given the preliminary evidence 
of clinical benefit in a heavily pretreated population with high disease burden, further 
evaluation is warranted and continues in the ongoing phase 2 clinical study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Demographics and Baseline Characteristics
Category
750 mg 600 mg 450 mg Total
n = 6 n = 6 n = 7 n = 19**
Age (yrs)† 65 (46, 86) 76 (52, 91) 61 (42, 77) 62 (42, 91)
Race‡
 White 6 (100) 6 (100) 6 (86) 18 (95)
 Black 0 (0) 0 (0) 1 (14) 1 (5)
 Other 0 (0) 0 (0) 0 (0) 0 (0)
BMI (kg/m2)† 22.5 (16.3, 36.0) 28.9 (22.3, 33.8) 32.6 (21.3, 46.7) 30.5 (16.3, 46.7)
Breast Cancer Type
 ER+ 6 (100) 5 (83) 3 (43) 14 (74)
 TNBC 0 (0) 1 (17) 4 (57) 5 (26)
Disease Status
 Locally Advanced‡ 0 (0) 0 (0) 1 (14) 1 (5)
 Bone Only‡ 0 (0) 0 (0) 0 (0) 0 (0)
 Visceral*,‡ 5 (83) 5 (83) 6 (86) 16 (84)
 Bone*,‡ 2 (33) 3 (50) 2 (29) 7 (37)
≥2 Prior Lines of Therapy for Advanced/Metastatic Disease‡ 6 (100) 5 (83) 6 (86) 17 (90)
 Chemotherapy Alone‡ 4 (67) 2 (33) 4 (57) 10 (53)
 Hormonal Therapy Alone‡ 0 0 1 (14) 1 (5)
 Hormonal and Chemotherapy‡ 2 (33) 3 (50) 1 (14) 6 (32)
*
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Table 3
Overview of Treatment-Emergent Adverse Events







Subjects with any AE† 6 (100) 6 (100) 7 (100) 19 (100)
Subjects with any SAE 3 (50) 4 (67) 5 (71) 12 (63)
Subjects with any drug-related AE 6 (100) 6 (100) 5 (71) 17 (90)
Subjects with any drug-related SAE 1 (17) 2 (33) 0 (0) 3 (16)
Subjects with AE leading to permanent discontinuation 0 (0) 1 (17) 1 (14) 2 (11)
Subjects with Any Gr 3 or Gr 4 AE 4 (67) 3 (50) 4 (57) 11 (58)
Subjects with any drug-related AE of Gr 3 or Gr 4 1 (17) 2 (33) 1 (14) 4 (21)
Subjects with AE leading to interruption 6 (100) 5 (83) 3 (43) 14 (74)
Subjects with AE leading to death 0 (0) 2 (33) 0 (0) 2 (11)
AE = adverse event; Gr = Grade; SAE = serious adverse event;
†
n (%)
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Table 4
Overview of Treatment Duration, Discontinuations and Dose Modifications
750 mg 600 mg 450 mg Total
n = 6 n = 6 n = 7 n = 19
Treatment Duration (days)† 35.5 (13, 168) 30 (13, 48) 136 (22, 257) 43 (13, 257)
Ongoing‡ 0 (0) 0 (0) 0 (0) 0 (0)
Discontinued‡ 6 (100) 6 (100) 7 (100) 19 (100)
Reason for Treatment Discontinuation‡
Progressive Disease 3 (50) 4 (67) 5 (71) 12 (63)
Adverse Event 0 (0) 1 (17) 1 (14) 2 (11)
Other 3 (50) 1 (17) 1 (14) 5 (26)
Adverse Event-Related Dose Modifications‡
Dose Interruption 5 (83) 4 (67) 4 (57) 13 (68)
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